Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.
Let’s Win! Pancreatic Cancer is an online community for sharing information about innovative, science-based treatments for pancreatic cancer. Please note that this information is not intended to be a substitute for professional medical opinion, advice, or diagnosis. We encourage you to use this information to begin a dialogue with your physician about the treatment plan that is right for you.